The Editorial Executive Committee welcomes letters, which should be less than 250 words. Before a decision to publish is made, letters which refer to a published article may be sent to the author for a response. Any letter may be sent to an expert for comment. When letters are published, they are usually accompanied in the same issue by their responses or comments. The Committee screens out discourteous, inaccurate or libellous statements. The letters are sub-edited before publication. Authors are required to declare any conflicts of interest. The Committee's decision on publication is final.
Letter to the Editor
Editor, – I read the letter by JF Walsh on bisphosphonates and osteonecrosis with interest (Aust Prescr 2010;33:167-70). Surely it is up to the treating clinician (for example the dental practitioner) to establish which medication a patient is on and assess their relative risks. Patients get overwhelmed with the list of potential side effects we inform them of. They quite rightly remember the common ones. A good drug history takes no time at all and dental practitioners should have this basic skill.